Who Paid My Doc
Research studies in the Open Payments record
139,921 studies have research funding reported against them. Being named on a study as a principal investigator is reported separately from being paid.
Studies
50 of 139,921- M21-572 - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No ClinicalTrials.gov identifier reported
- M21-572 Ph3 Ped FC Trial 2-5 (LIN-MD-68) (3051-303-001) NCT05652205
- M21-841 - M21-841 NOA Volume - Mid Face US Pivotal Study No ClinicalTrials.gov identifier reported
- M21-841 NOA Volume - Mid Face US Pivotal Study No ClinicalTrials.gov identifier reported
- M21-841 NOA Volume - Mid Face US Pivotal Study NCT06734351
- M21-862 - A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No ClinicalTrials.gov identifier reported
- M21-862 Ph2 6 mo-2 yr old Functional Constipation Study (3051-201-001) NCT05760313
- M22-003 PH 3 1L - Chemo Free - Epco + Revlimid NCT06191744
- M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No ClinicalTrials.gov identifier reported
- M22-087 - A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No ClinicalTrials.gov identifier reported
- M22-128 - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No ClinicalTrials.gov identifier reported
- M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No ClinicalTrials.gov identifier reported
- M22-132 Epcoritamab PH 2 Basket Combo Study NCT05283720
- M22-418 Atogepant-Botox Combination Study NCT05216263
- M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No ClinicalTrials.gov identifier reported
- M22-574 - Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No ClinicalTrials.gov identifier reported
- M22-716 ABBV-319 FIH B-cell Malignancies NCT05512390
- M22-721 ABBV-916 Ph 1-2 MAD with POC in AD NCT05291234
- M22-721 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No ClinicalTrials.gov identifier reported
- M22-947 - A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No ClinicalTrials.gov identifier reported
- M22-974 - A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administration of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Upper Facial Lines (Glabellar Lines Lateral Canthal Lines and Forehead Lines) No ClinicalTrials.gov identifier reported
- M22-974 BOTOX GL-FHL-CFL Phase 4 NCT06218251
- M23-001 - Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma No ClinicalTrials.gov identifier reported
- M23-324 PH 1 Dose Escalation-Expansion NCT05618028
- M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No ClinicalTrials.gov identifier reported
- M23-362 Ph2 Epcoritamab RR DLBCL and FL Outpatient Study NCT05451810
- M23-385 ABBV-706 Ph 1 2L-4L SCLC NCT05599984
- M23-471 - M23-471 Ph1b Target Occupancy PET No ClinicalTrials.gov identifier reported
- M23-471 Ph1b Target Occupancy PET NCT05028569
- M23-471 Ph1b Target Occupancy PET No ClinicalTrials.gov identifier reported
- M23-471 Ph1b Target Occupancy PET NCT05125302
- M23-477 ABBV-787 Ph 1 3L AML Study NCT06068868
- M23-499 PH 2 Spasticity NCT05956509
- M23-499 - Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity No ClinicalTrials.gov identifier reported
- M23-515 Ph2 AD Global Study NCT05771428
- M23-515 - Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No ClinicalTrials.gov identifier reported
- M23-647 ABBV-101 Ph1 RR NHL FIH NCT05753501
- M23-696 - A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No ClinicalTrials.gov identifier reported
- M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No ClinicalTrials.gov identifier reported
- M23-698 Rinvoq Ph3 1L HS Bio-IR (Step-Up) NCT05889182
- M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No ClinicalTrials.gov identifier reported
- M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No ClinicalTrials.gov identifier reported
- M23-700 Upa Phase 4 RA Select Switch NCT05814627
- M23-702 Skyrizi Ph4 PsO (Special Areas-Genital-Scalp) NCT05969223
- M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No ClinicalTrials.gov identifier reported
- M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No ClinicalTrials.gov identifier reported
- M23-712 - A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No ClinicalTrials.gov identifier reported
- M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No ClinicalTrials.gov identifier reported
- M23-714 Ubrelvy Menstrual Migraine NCT06417775
- M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No ClinicalTrials.gov identifier reported